Answers are grounded in this paper and cite their sources.
Restriction to Sorafenib-induced ferroptosis in hepatocellular carcinoma (HCC) involves poorly understood mitochondrial dysfunction. Using biochemical assays, orthotopic and patient-derived xenograft (PDX) models, and clinical microarrays, we discover that Sorafenib triggers a metabolic self-limiting effect. Mechanistically, Sorafenib inhibits mTOR to upregulate SIRT4, which mono-ADP-ribosylates (MARylates) GLUD1 at arginine 60 (R60), suppressing its enzymatic activity. Concurrently, mitophagy recruits MARylated GLUD1 to lysosomes, where the E3 ligase DTX3L specifically recognizes the modification via its DTC domain. DTX3L then non-canonically ubiquitinates the 3'-hydroxyl group of the ADP-ribose moiety, driving GLUD1 proteasomal degradation. This dual suppression specifically blocks glutamate-to-α-ketoglutarate (α-KG) conversion, starving the TCA cycle and impairing Electron Transport Chain (ETC) activity, thereby preventing lipid peroxidation. Clinically, the GLUD1/SIRT4 expression profile predicts relapse-free survival in HCC patients. Crucially, bypassing this blockade via α-KG supplementation refuels the TCA cycle and restores ETC-driven lipid ROS generation, yielding profound synergistic benefits with Sorafenib, particularly in PDX models with low GLUD1 enzymatic activity. Thus, R60 MARylation of GLUD1 constitutes a critical barrier to Sorafenib-induced ferroptosis. Targeting this mTOR/SIRT4/DTX3L cascade or replenishing α-KG represents a promising precision strategy to overcome Sorafenib resistance.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: